Crestline Management, LP Neurocrine Biosciences Inc Transaction History

Crestline Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 15, 2018	SELL	$75.88 - $92.43 $1.42 Million - $1.72 Million	-18,660 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$58.53 - $77.59 $2.6 Million - $3.44 Million	-44,369 Reduced 70.39%	18,660 $1.45 Million
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $881,256 - $1.13 Million	18,371 Added 41.14%	63,029 $3.86 Million
Q2 2017 Aug 14, 2017	BUY	N/A	44,658	44,658 $2.05 Million

638

93.8M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $14.5B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Crestline Management, LP, based on Form 13F filings with the SEC.

Stay updated on Crestline Management, LP with notifications on news.